Syndax Pharmaceuticals (SNDX) Total Debt (2015 - 2024)

Syndax Pharmaceuticals' Total Debt history runs 5 years deep, the most recent figure standing at $343.7 million for Q4 2024.

• In Q4 2024, Total Debt changed N/A year-over-year to $343.7 million; the TTM figure through Dec 2024 stood at $343.7 million (changed N/A YoY), while the FY2024 annual figure was $343.7 million, changed N/A from the prior year.
• Total Debt was $343.7 million for Q4 2024 at Syndax Pharmaceuticals, up from $20.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $343.7 million in Q4 2024 to a low of $19.8 million in Q1 2020.
• Historically, Total Debt has averaged $49.5 million across 4 years, with a median of $20.1 million in 2020.
• The sharpest annual moves came in 2021 and 2022: Total Debt rose 2.36% in 2021, then fell 0.92% in 2022.
• A 4-year view of Total Debt shows it stood at $20.1 million in 2020, then declined by 0.18% to $20.1 million in 2021, then grew by 0.62% to $20.2 million in 2022, then surged by 1600.89% to $343.7 million in 2024.
• The last three Total Debt figures came in at $343.7 million (Q4 2024), $20.2 million (Q2 2022), and $20.0 million (Q1 2022), per Business Quant data.